Heart Failure. A State of Brain Natriuretic Peptide Deficiency or Resistance or Both!

Journal of the American College of Cardiology

Volumn 49, Issue 10, 2007, Pages 1089-1091

  Chen, Horng H ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; MESSENGER RNA; PROTEIN SUBUNIT; SILDENAFIL;

CONGESTIVE CARDIOMYOPATHY; DISEASE CLASSIFICATION; DRUG MECHANISM; EDITORIAL; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORMONE RESISTANCE; HUMAN; IMMUNOREACTIVITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

ANIMALS; BIOLOGICAL MARKERS; CARDIAC OUTPUT; DISEASE MODELS, ANIMAL; DOGS; HEART FAILURE, CONGESTIVE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PHOSPHODIESTERASE INHIBITORS; REFERENCE VALUES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 33847785230     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.12.013     Document Type: Editorial

References (17)

1. Francis G.S., Benedict C., Johnstone D.E., et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation 82 (1990) 1724-1729
2. The SOLVD Investigators. Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991) 293-302
3. Liang F., O'Rear J., Schellenberger U., et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol 49 (2007) 1071-1078
4. Forfia P.R., Lee M., Tunin R.S., Mahmud M., Champion H.C., and Kass D.A. Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart. J Am Coll Cardiol 49 (2007) 1079-1088
5. Chen H.H., and Burnett Jr. J.C. The natriuretic peptides in heart failure: diagnostic and therapeutic potentials. (review). Proc Assoc Am Physicians 111 (1999) 406-416
6. Luchner A., Stevens T.L., Borgeson D.D., et al. Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol 274 (1998) H1684-H1689
7. Stevens T.L., Burnett Jr. J.C., Kinoshita M., Matsuda Y., and Redfield M.M. A functional role for endogenous atrial natriuretic peptide in a canine model of early left ventricular dysfunction. J Clin Invest 95 (1995) 1101-1108
8. Redfield M.M., Edwards B.S., McGoon M.D., Heublein D.M., Aarhus L.L., and Burnett Jr. J.C. Failure of atrial natriuretic factor to increase with volume expansion in acute and chronic congestive heart failure in the dog. Circulation 80 (1989) 651-657
9. Volpe M., Tritto C., De Luca N., et al. Failure of atrial natriuretic peptide to increase with saline load in patients with dilated cardiomyopathy and mild heart failure. J Clin Invest 88 (1993) 1481-1489
10. Shimizu H., Masuta K., Aono K., et al. Molecular forms of human brain natriuretic peptide in plasma. Clin Chim Acta 316 (2002) 129-135
11. Hawkridge A.M., Heublein D.M., Bergen III H.R., Cataliotti A., Burnett Jr. J.C., and Muddiman D.C. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci U S A 102 (2005) 17442-17447
12. Chen H.H., Schirger J.A., Chau W.L., et al. Renal response to acute neutral endopeptidase inhibition in mild and severe experimental heart failure. Circulation 100 (1999) 2443-2448
13. Charloux A., Piquard F., Doutreleau S., Brandenberger G., and Geny B. Mechanisms of renal hyporesponsiveness to ANP in heart failure. Eur J Clin Invest 33 (2003) 769-778
14. Wilkins M.R., Settle S.L., and Needleman P. Augmentation of the natriuretic activity of exogenous and endogenous atriopeptin in rats by inhibition of guanosine 3′,5′-cyclic monophosphate degradation. J Clin Invest 85 (1990) 1274-1279
15. Supaporn T., Sandberg S.M., Borgeson D.D., et al. Blunted cGMP response to agonists and enhanced glomerular cyclic 3′,5′-nucleotide phosphodiesterase activities in experimental congestive heart failure. Kidney Int 50 (1996) 1718-1725
16. Chen H.H., Huntley B.K., Schirger J.A., Cataliotti A., and Burnett Jr. J.C. Maximizing the renal cyclic 3′-5′-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure. J Am Soc Nephrol 17 (2006) 2742-2747
17. Riter H.G., Redfield M.M., Burnett J.C., and Chen H.H. Nonhypotensive low-dose nesiritide has differential renal effects compared with standard-dose nesiritide in patients with acute decompensated heart failure and renal dysfunction. J Am Coll Cardiol 47 (2006) 2334-2335